0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neuromyelitis Optica Drug Market Research Report 2024
Published Date: January 2024
|
Report Code: QYRE-Auto-16A2404
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Neuromyelitis Optica Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Global Neuromyelitis Optica Drug Market Research Report 2024

Code: QYRE-Auto-16A2404
Report
January 2024
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Neuromyelitis Optica Drug Market Size

The global Neuromyelitis Optica Drug market was valued at US$ 47 million in 2023 and is anticipated to reach US$ 58 million by 2030, witnessing a CAGR of 3.0% during the forecast period 2024-2030.

Neuromyelitis Optica Drug Market

Neuromyelitis Optica Drug Market

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.

Report Scope

The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Neuromyelitis Optica Drug Market Report

Report Metric Details
Report Name Neuromyelitis Optica Drug Market
Accounted market size in 2023 US$ 47 million
Forecasted market size in 2030 US$ 58 million
CAGR 3.0%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Glucocorticoids
  • Immunotherapies
  • Others
Segment by Application
  • Acute Attack
  • Remission Prophylactic Treatment
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Neuromyelitis Optica Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Neuromyelitis Optica Drug Market growing?

Ans: The Neuromyelitis Optica Drug Market witnessing a CAGR of 3.0% during the forecast period 2024-2030.

What is the Neuromyelitis Optica Drug Market size in 2030?

Ans: The Neuromyelitis Optica Drug Market size in 2030 will be US$ 58 million.

What is the Neuromyelitis Optica Drug Market share by region?

Ans: Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

What is the market share of major companies in Neuromyelitis Optica Drug Market?

Ans: Top 3 companies occupied about 35% market share.

Who are the main players in the Neuromyelitis Optica Drug Market report?

Ans: The main players in the Neuromyelitis Optica Drug Market are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP

What are the Application segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Applications covered in the Neuromyelitis Optica Drug Market report are Acute Attack, Remission Prophylactic Treatment

What are the Type segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Types covered in the Neuromyelitis Optica Drug Market report are Glucocorticoids, Immunotherapies, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Drug Market Perspective (2019-2030)
2.2 Neuromyelitis Optica Drug Growth Trends by Region
2.2.1 Global Neuromyelitis Optica Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2019-2024)
2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2025-2030)
2.3 Neuromyelitis Optica Drug Market Dynamics
2.3.1 Neuromyelitis Optica Drug Industry Trends
2.3.2 Neuromyelitis Optica Drug Market Drivers
2.3.3 Neuromyelitis Optica Drug Market Challenges
2.3.4 Neuromyelitis Optica Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Drug Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2019-2024)
3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2019-2024)
3.2 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuromyelitis Optica Drug Revenue
3.4 Global Neuromyelitis Optica Drug Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2023
3.5 Neuromyelitis Optica Drug Key Players Head office and Area Served
3.6 Key Players Neuromyelitis Optica Drug Product Solution and Service
3.7 Date of Enter into Neuromyelitis Optica Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Drug Breakdown Data by Type
4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2019-2024)
4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2025-2030)
5 Neuromyelitis Optica Drug Breakdown Data by Application
5.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2019-2024)
5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neuromyelitis Optica Drug Market Size (2019-2030)
6.2 North America Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neuromyelitis Optica Drug Market Size by Country (2019-2024)
6.4 North America Neuromyelitis Optica Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Drug Market Size (2019-2030)
7.2 Europe Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neuromyelitis Optica Drug Market Size by Country (2019-2024)
7.4 Europe Neuromyelitis Optica Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size (2019-2030)
8.2 Asia-Pacific Neuromyelitis Optica Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Drug Market Size (2019-2030)
9.2 Latin America Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neuromyelitis Optica Drug Market Size by Country (2019-2024)
9.4 Latin America Neuromyelitis Optica Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Drug Market Size (2019-2030)
10.2 Middle East & Africa Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuromyelitis Optica Drug Introduction
11.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Fresenius
11.2.1 Fresenius Company Detail
11.2.2 Fresenius Business Overview
11.2.3 Fresenius Neuromyelitis Optica Drug Introduction
11.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.2.5 Fresenius Recent Development
11.3 Teva
11.3.1 Teva Company Detail
11.3.2 Teva Business Overview
11.3.3 Teva Neuromyelitis Optica Drug Introduction
11.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.3.5 Teva Recent Development
11.4 Sandoz
11.4.1 Sandoz Company Detail
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Neuromyelitis Optica Drug Introduction
11.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.4.5 Sandoz Recent Development
11.5 Intas
11.5.1 Intas Company Detail
11.5.2 Intas Business Overview
11.5.3 Intas Neuromyelitis Optica Drug Introduction
11.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.5.5 Intas Recent Development
11.6 Gyjtrs
11.6.1 Gyjtrs Company Detail
11.6.2 Gyjtrs Business Overview
11.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction
11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.6.5 Gyjtrs Recent Development
11.7 NANG KUANG
11.7.1 NANG KUANG Company Detail
11.7.2 NANG KUANG Business Overview
11.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction
11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.7.5 NANG KUANG Recent Development
11.8 Tianjin Kingyork
11.8.1 Tianjin Kingyork Company Detail
11.8.2 Tianjin Kingyork Business Overview
11.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction
11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.8.5 Tianjin Kingyork Recent Development
11.9 Baxter
11.9.1 Baxter Company Detail
11.9.2 Baxter Business Overview
11.9.3 Baxter Neuromyelitis Optica Drug Introduction
11.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.9.5 Baxter Recent Development
11.10 CSL
11.10.1 CSL Company Detail
11.10.2 CSL Business Overview
11.10.3 CSL Neuromyelitis Optica Drug Introduction
11.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.10.5 CSL Recent Development
11.11 Grifols
11.11.1 Grifols Company Detail
11.11.2 Grifols Business Overview
11.11.3 Grifols Neuromyelitis Optica Drug Introduction
11.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.11.5 Grifols Recent Development
11.12 Octapharma
11.12.1 Octapharma Company Detail
11.12.2 Octapharma Business Overview
11.12.3 Octapharma Neuromyelitis Optica Drug Introduction
11.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.12.5 Octapharma Recent Development
11.13 CBOP
11.13.1 CBOP Company Detail
11.13.2 CBOP Business Overview
11.13.3 CBOP Neuromyelitis Optica Drug Introduction
11.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2019-2024)
11.13.5 CBOP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Glucocorticoids
    Table 3. Key Players of Immunotherapies
    Table 4. Key Players of Others
    Table 5. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Neuromyelitis Optica Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Neuromyelitis Optica Drug Market Share by Region (2019-2024)
    Table 9. Global Neuromyelitis Optica Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Neuromyelitis Optica Drug Market Share by Region (2025-2030)
    Table 11. Neuromyelitis Optica Drug Market Trends
    Table 12. Neuromyelitis Optica Drug Market Drivers
    Table 13. Neuromyelitis Optica Drug Market Challenges
    Table 14. Neuromyelitis Optica Drug Market Restraints
    Table 15. Global Neuromyelitis Optica Drug Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Neuromyelitis Optica Drug Market Share by Players (2019-2024)
    Table 17. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2023)
    Table 18. Ranking of Global Top Neuromyelitis Optica Drug Companies by Revenue (US$ Million) in 2023
    Table 19. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Neuromyelitis Optica Drug Product Solution and Service
    Table 22. Date of Enter into Neuromyelitis Optica Drug Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2024)
    Table 26. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2025-2030)
    Table 28. Global Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2019-2024)
    Table 30. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2025-2030)
    Table 32. North America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 33. North America Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 34. North America Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 35. Europe Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 36. Europe Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 37. Europe Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 38. Asia-Pacific Neuromyelitis Optica Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 39. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 40. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2025-2030) & (US$ Million)
    Table 41. Latin America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 42. Latin America Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 43. Latin America Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 44. Middle East & Africa Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 47. Pfizer Company Detail
    Table 48. Pfizer Business Overview
    Table 49. Pfizer Neuromyelitis Optica Drug Product
    Table 50. Pfizer Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 51. Pfizer Recent Development
    Table 52. Fresenius Company Detail
    Table 53. Fresenius Business Overview
    Table 54. Fresenius Neuromyelitis Optica Drug Product
    Table 55. Fresenius Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 56. Fresenius Recent Development
    Table 57. Teva Company Detail
    Table 58. Teva Business Overview
    Table 59. Teva Neuromyelitis Optica Drug Product
    Table 60. Teva Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 61. Teva Recent Development
    Table 62. Sandoz Company Detail
    Table 63. Sandoz Business Overview
    Table 64. Sandoz Neuromyelitis Optica Drug Product
    Table 65. Sandoz Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 66. Sandoz Recent Development
    Table 67. Intas Company Detail
    Table 68. Intas Business Overview
    Table 69. Intas Neuromyelitis Optica Drug Product
    Table 70. Intas Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 71. Intas Recent Development
    Table 72. Gyjtrs Company Detail
    Table 73. Gyjtrs Business Overview
    Table 74. Gyjtrs Neuromyelitis Optica Drug Product
    Table 75. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 76. Gyjtrs Recent Development
    Table 77. NANG KUANG Company Detail
    Table 78. NANG KUANG Business Overview
    Table 79. NANG KUANG Neuromyelitis Optica Drug Product
    Table 80. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 81. NANG KUANG Recent Development
    Table 82. Tianjin Kingyork Company Detail
    Table 83. Tianjin Kingyork Business Overview
    Table 84. Tianjin Kingyork Neuromyelitis Optica Drug Product
    Table 85. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 86. Tianjin Kingyork Recent Development
    Table 87. Baxter Company Detail
    Table 88. Baxter Business Overview
    Table 89. Baxter Neuromyelitis Optica Drug Product
    Table 90. Baxter Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 91. Baxter Recent Development
    Table 92. CSL Company Detail
    Table 93. CSL Business Overview
    Table 94. CSL Neuromyelitis Optica Drug Product
    Table 95. CSL Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 96. CSL Recent Development
    Table 97. Grifols Company Detail
    Table 98. Grifols Business Overview
    Table 99. Grifols Neuromyelitis Optica Drug Product
    Table 100. Grifols Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 101. Grifols Recent Development
    Table 102. Octapharma Company Detail
    Table 103. Octapharma Business Overview
    Table 104. Octapharma Neuromyelitis Optica Drug Product
    Table 105. Octapharma Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 106. Octapharma Recent Development
    Table 107. CBOP Company Detail
    Table 108. CBOP Business Overview
    Table 109. CBOP Neuromyelitis Optica Drug Product
    Table 110. CBOP Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)
    Table 111. CBOP Recent Development
    Table 112. Research Programs/Design for This Report
    Table 113. Key Data Information from Secondary Sources
    Table 114. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neuromyelitis Optica Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Neuromyelitis Optica Drug Market Share by Type: 2023 VS 2030
    Figure 3. Glucocorticoids Features
    Figure 4. Immunotherapies Features
    Figure 5. Others Features
    Figure 6. Global Neuromyelitis Optica Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 7. Global Neuromyelitis Optica Drug Market Share by Application: 2023 VS 2030
    Figure 8. Acute Attack Case Studies
    Figure 9. Remission Prophylactic Treatment Case Studies
    Figure 10. Neuromyelitis Optica Drug Report Years Considered
    Figure 11. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 12. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Neuromyelitis Optica Drug Market Share by Region: 2023 VS 2030
    Figure 14. Global Neuromyelitis Optica Drug Market Share by Players in 2023
    Figure 15. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2023)
    Figure 16. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2023
    Figure 17. North America Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 18. North America Neuromyelitis Optica Drug Market Share by Country (2019-2030)
    Figure 19. United States Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. Canada Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. Europe Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Europe Neuromyelitis Optica Drug Market Share by Country (2019-2030)
    Figure 23. Germany Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. France Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. U.K. Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Italy Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Russia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Nordic Countries Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Asia-Pacific Neuromyelitis Optica Drug Market Share by Region (2019-2030)
    Figure 31. China Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Japan Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. South Korea Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. India Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Australia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Latin America Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Latin America Neuromyelitis Optica Drug Market Share by Country (2019-2030)
    Figure 39. Mexico Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Brazil Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Middle East & Africa Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Middle East & Africa Neuromyelitis Optica Drug Market Share by Country (2019-2030)
    Figure 43. Turkey Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Saudi Arabia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 46. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 47. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 48. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 49. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 50. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 51. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 52. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 53. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 54. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 55. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 56. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 57. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)
    Figure 58. Bottom-up and Top-down Approaches for This Report
    Figure 59. Data Triangulation
    Figure 60. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS